We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Portola, HealthCare Royalty Partners Ink $150 Million Deal
Read MoreHide Full Article
Portola Pharmaceuticals, Inc.’s shares were up 2.7% after the company announced that it has signed a royalty agreement with HealthCare Royalty Partners (HCR), a private investment firm, for $150 million.
A look at Portola’s share price movement over the past one year shows that the stock has underperformed the Zacks classified Medical-Drugs industry. Specifically, the company’s stock increased 0.6% during this period, while the industry gained 2.1%.
Terms of the Agreement
Portola received $50 million on the closing of the agreement. In addition, the company is eligible to receive $100 million upon the U.S. approval of AndexXa (andexanet alfa) in exchange for tiered, mid-single-digit royalty based on worldwide sales.
The agreement is subject to a maximum total royalty payment of 195% of the $150 million funding by HCR.
Portola stated that it will use the proceeds for clinical and regulatory activities, and planned development and commercialization of AndexXa (EU trade name: IndexXa). Note that AndexXa is in development as a potential antidote for Factor Xa inhibitors.
We remind investors in Aug 2016, the FDA issued a complete response letter (CRL) for AndexXa, which was being developed as an antidote for Factor Xa inhibitors, in cases where reversal of anticoagulation is needed due to life-threatening bleeding or when urgent surgery is required. Portola plans to resubmit the biologics license application for AndexXa in the first half of 2017.
Meanwhile, AndexXa is currently under review in the EU. Note that with no currently approved antidote for Factor Xa inhibitors, there is high unmet need for the same in the market.
Interestingly, Portola had been signing collaborations for quite a while now for the potential development of AndexXa. In Dec 2016, the company signed a $50 million loan agreement with Bristol-Myers Squibb Company (BMY - Free Report) and Pfizer Inc. (PFE - Free Report) , under which Bristol-Myers and Pfizer will each loan Portola $25 million for development and clinical studies on AndexXa.
Going ahead, we expect investor focus to remain on further details on the regulatory aspect of AndexXa.
Portola currently carries a Zacks Rank #3 (Hold). Sucampo Pharmaceuticals, Inc. is a better-ranked stock in the health care with a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings estimates were stable at $1.22 for 2016 but have increased from $1.58 to $1.74 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 35.5%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Portola, HealthCare Royalty Partners Ink $150 Million Deal
Portola Pharmaceuticals, Inc.’s shares were up 2.7% after the company announced that it has signed a royalty agreement with HealthCare Royalty Partners (HCR), a private investment firm, for $150 million.
A look at Portola’s share price movement over the past one year shows that the stock has underperformed the Zacks classified Medical-Drugs industry. Specifically, the company’s stock increased 0.6% during this period, while the industry gained 2.1%.
Terms of the Agreement
Portola received $50 million on the closing of the agreement. In addition, the company is eligible to receive $100 million upon the U.S. approval of AndexXa (andexanet alfa) in exchange for tiered, mid-single-digit royalty based on worldwide sales.
The agreement is subject to a maximum total royalty payment of 195% of the $150 million funding by HCR.
Portola stated that it will use the proceeds for clinical and regulatory activities, and planned development and commercialization of AndexXa (EU trade name: IndexXa). Note that AndexXa is in development as a potential antidote for Factor Xa inhibitors.
We remind investors in Aug 2016, the FDA issued a complete response letter (CRL) for AndexXa, which was being developed as an antidote for Factor Xa inhibitors, in cases where reversal of anticoagulation is needed due to life-threatening bleeding or when urgent surgery is required. Portola plans to resubmit the biologics license application for AndexXa in the first half of 2017.
Meanwhile, AndexXa is currently under review in the EU. Note that with no currently approved antidote for Factor Xa inhibitors, there is high unmet need for the same in the market.
Interestingly, Portola had been signing collaborations for quite a while now for the potential development of AndexXa. In Dec 2016, the company signed a $50 million loan agreement with Bristol-Myers Squibb Company (BMY - Free Report) and Pfizer Inc. (PFE - Free Report) , under which Bristol-Myers and Pfizer will each loan Portola $25 million for development and clinical studies on AndexXa.
Going ahead, we expect investor focus to remain on further details on the regulatory aspect of AndexXa.
Portola Pharmaceuticals, Inc. Price and Consensus
Portola Pharmaceuticals, Inc. Price and Consensus | Portola Pharmaceuticals, Inc. Quote
Zacks Rank & Key Picks
Portola currently carries a Zacks Rank #3 (Hold). Sucampo Pharmaceuticals, Inc. is a better-ranked stock in the health care with a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Sucampo’s earnings estimates were stable at $1.22 for 2016 but have increased from $1.58 to $1.74 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 35.5%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>